Internal Med Medical News about Exenatide Sitagliptin

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Bevacizumab + Interferon Alfa Approved for Renal Cell Carcinoma

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Strategic Therapy of Glioblastoma Gains Ground

Sara Hartley

Technology Advances

A New Strategy for Protecting Ovaries in Young Cancer Patients

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

FDA Approves Revisions to Prescribing Information for Diabetes Medications
American Family Physician, 11/06/09

The FDA is revising the prescribing information for the injectable diabetes medication exenatide and the oral diabetes drug sitagliptin phosphate following reports of renal problems associated with exenatide use, as well as reports linking sitagliptin use with pancreatitis.

<< Previous
Detection rate and factors predictive the presence of prostate...

Next >>
The Catatonia Syndrome: Forgotten but Not Gone